COL9A1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09539(COL9A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The COL9A1 antibody targets the alpha-1 chain of type IX collagen, a critical component of the extracellular matrix (ECM). Encoded by the COL9A1 gene, this chain combines with α2 and α3 chains (from COL9A2 and COL9A3) to form heterotrimeric type IX collagen, a fibril-associated collagen with interrupted triple helices (FACIT). This collagen type interacts with type II collagen in cartilage, stabilizing fibrillar networks and mediating ECM-cell signaling. COL9A1 is vital for maintaining structural integrity in articular cartilage, intervertebral discs, and other connective tissues.

Mutations in COL9A1 are linked to musculoskeletal disorders, including Stickler syndrome, multiple epiphyseal dysplasia (EDM2), and early-onset osteoarthritis. Antibodies against COL9A1 are used in research to study collagen assembly, tissue development, and disease mechanisms. They enable detection of COL9A1 expression and distribution via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Such studies help clarify how COL9A1 dysfunction contributes to ECM degradation in degenerative diseases. Additionally, these antibodies aid in diagnosing genetic collagenopathies by identifying abnormal protein expression in patient samples. Commercial COL9A1 antibodies are typically raised in rabbits or mice, with specificity validated in human, mouse, or rat tissues. Understanding COL9A1's role through antibody-based research supports therapeutic development targeting collagen-related pathologies.